Xenon Pharmaceuticals Inc (XENE)

followers · Follow

Sector:	HEALTH CARE
Industry:	BIOTECHNOLOGY & LIFE SCIENCES
SIC:	PHARMACEUTICAL PREPARATIONS
CEO:	Ian C. Mortimer
Employees:	210
Web site:	xenon-pharma.com
200 - 3650 GILMORE WAY, BURNABY, A1, V5G 48W (604) 484-3300

	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change

Xenon Pharmaceuticals Inc. engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy. XEN007, a central nervous system-acting calcium channel modulator, is in Phase II clinical trials.

Please log in first to see chart

Xenon Pharmaceuticals Inc YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Shareholders (13F, 13D/G)

Current Mutual Fund/ETF Holders

Active 13D/G Filings

SEC Filings

Insiders

Short Positions

Congress

Proposed Sales

Comments and Updates

To Excel | To CSV | To TSV

Investor	History	Shares Held or Principal Amt	Market Value	% of Portfolio	Previous % of Portfolio	Rank	Change in Shares	% Change in Shares	% Ownership	Qtr 1st Owned	Est. Avg Price	Source	Source Date	Date Reported
No data available